stoxline Quote Chart Rank Option Currency Glossary
  
Connect Biopharma Holdings Limited (CNTB)
0.6282  -0.037 (-5.56%)    11-19 16:00
Open: 0.6352
High: 0.6459
Volume: 485,827
  
Pre. Close: 0.6652
Low: 0.591
Market Cap: 41(M)
Technical analysis
2026-11-19 4:33:58 PM
Short term     
Mid term     
Targets 6-month :  0.9 1-year :  1.07
Resists First :  0.77 Second :  0.92
Pivot price 0.7
Supports First :  0.55 Second :  0.45
MAs MA(5) :  0.63 MA(20) :  0.73
MA(100) :  1.59 MA(250) :  2.15
MACD MACD :  -0.2 Signal :  -0.2
%K %D K(14,3) :  22.7 D(3) :  18.5
RSI RSI(14): 33.4
52-week High :  3.81 Low :  0.55
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ CNTB ] has closed above bottom band by 19.4%. Bollinger Bands are 59.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 28 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.65 - 0.65 0.65 - 0.65
Low: 0.58 - 0.59 0.59 - 0.59
Close: 0.62 - 0.63 0.63 - 0.63
Company Description

Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical company dedicated to discovering and advancing immune modulators. Its primary objective is to develop treatments for serious autoimmune diseases and various inflammatory conditions. The company's lead investigational therapy is CBP-201, an anti-interleukin-4 receptor alpha antibody. This candidate is currently in Phase IIb clinical trials, targeting inflammatory allergic diseases such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Additionally, Connect Biopharma's pipeline includes CBP-307, a small molecule designed to modulate sphingosine 1-phosphate receptor 1. This receptor plays a crucial role in regulating T cell movement from lymph nodes into the bloodstream. CBP-307 is in Phase II development for treating autoimmune-related inflammatory disorders. Another preclinical-stage asset, CBP-174, is an orally administered small molecule histamine receptor 3 antagonist, being investigated for chronic pruritus (itch) associated with skin inflammation. The portfolio also features CBP-233, a humanized antibody in preclinical development that targets interleukin-33, a cytokine recognized for its involvement in T helper 2 inflammation. Established in 2012, the company maintains its headquarters in Taicang, China.

Headline News

Tue, 17 Nov 2026
Connect Biopharma Holdings Limited (CNTB) Stock Price, News, Quote & History - Yahoo! Finance Canada

Fri, 30 Oct 2026
Connect Biopharma Holdings (NasdaqGM:CNTB) Stock Forecast & Analyst Predictions - Simply Wall St

Thu, 22 Oct 2026
Down 25.4% in 4 Weeks, Here's Why Connect Biopharma Holdings (CNTB) Looks Ripe for a Turnaround - Yahoo Finance

Thu, 01 Oct 2026
CNTB Stock Slides Toward $1 As Biotech Traders Refocus - StocksToTrade

Wed, 30 Sep 2026
CNTB Stock Whipsaws As Traders Weigh Mixed Trial Data And Analyst Cuts - StocksToTrade

Wed, 30 Sep 2026
Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adults with COPD and Type 2 Inflammation - GlobeNewswire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 0 (M)
Shares Float 63 (M)
Held by Insiders 2.214e+007 (%)
Held by Institutions 30.3 (%)
Shares Short 2,770 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -6.973e+007
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -636 %
Return on Assets (ttm) -69.8 %
Return on Equity (ttm) -140.6 %
Qtrly Rev. Growth 5 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth -1.2 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -61 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales 0
Price to Cash Flow 0
Stock Dividends
Dividend 0
Forward Dividend 3.86e+006
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

Stoxline iOS

Alpha Bridge iOS

OptionCalc iOS

StockChart Android

Stoxline Android

Alpha Bridge Android

OptionCalc Android